Ki-67 Levels and Their Association With Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Prospective Observational Study

April 2025 in “ Cureus ”

R. Narendra, Chellappa Vijayakumar, G.S. Haritha, Suresh Kumar, Krishnamachari Srinivasan, Biswajit Dubashi, Ashok Badhe Bhawana, Sundar Elangovan

Studysummary In this study, among Indian patients with triple-negative breast cancer, Ki-67 expression levels were high but not significantly associated with treatment response to a neoadjuvant docetaxel-carboplatin regimen, which showed complete clinical, imaging, and pathological response rates of 39.13%, 34.78%, and 47.61%, respectively.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on assets.cureus.com →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research The evolution of primary multimodality treatment in resectable breast cancer

13 citations , August 1980 in “Cancer”

This study found that administering chemotherapy to premenopausal women with Stage II breast cancer significantly improved disease-free intervals and increased survival, while postmenopausal women receiving sufficient doses also saw prolonged disease-free periods.

research Label-free multiphoton imaging to assess neoadjuvant therapy responses in breast carcinoma

14 citations , January 2020 in “International Journal of Biological Sciences”

This study explored the use of multiphoton microscopy to monitor changes in tumors and surrounding tissues in breast cancer patients undergoing neoadjuvant chemotherapy, finding it may effectively detect treatment response at cellular levels without using exogenous contrast agents.

research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

1 citations , July 2021 in “Frontiers in Oncology”

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

research 200 The relationship between the expression of cytokeratin 5/6 and clinicopathologic factors in invasive breast carcinoma

March 2010 in “Ejc Supplements”

This review discusses the paradoxical effects of valproic acid on hair, noting that it can both cause alopecia and stimulate hair growth, but reports no new experimental findings.

A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer

research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer

January 2025 in “Recent Patents on Anti-Cancer Drug Discovery”

In this study, neoadjuvant treatment with durvalumab combined with albumin-bound paclitaxel and carboplatin in patients with driver gene-negative stage III NSCLC showed a 65% objective response rate and was associated with high pathological response rates and improved immune function, with most adverse events being mild.